FDA approves new kind of oral diabetes drug
The Food and Drug Administration recently approved a new kind of type 2 diabetes drug to help better control glucose levels.
“Invokana is the first diabetes treatment approved in a new class of drugs known as sodium-glucose co-transporter 2 (SGLT2) inhibitors,” said Mary Parks, M.D., director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research.
The drug prevents the kidney from reabsorbing glucose, according to the FDA. It increases glucose excretion in urine and lowers blood glucose for those with elevated levels.
Long-term care providers should note that Invokana has been known to cause dizziness while standing, which could lead to people falling. Urinary tract infections, weight loss and reduced systolic blood pressure are among the other side effects.
The drug is taken orally, once a day. It will be sold by Johnson & Johnson at a wholesale price of $8.77 per tablet, according to The New York Times.